Combination PD-1 blockade and irradiation of brain metastasis induces an effective abscopal effect in melanoma.
Melanoma
antibody therapy
immunomodulation
immunotherapy
radiotherapy
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
Historique:
received:
11
04
2018
revised:
02
07
2018
accepted:
01
08
2018
entrez:
15
12
2018
pubmed:
14
12
2018
medline:
14
12
2018
Statut:
epublish
Résumé
Nearly half of melanoma patients develop brain metastases during the course of their disease. Despite advances in both localized radiation and systemic immunotherapy, brain metastases remain difficult to treat, with most patients surviving less than 5 months from the time of diagnosis. While both treatment regimens have individually shown considerable promise in treating metastatic melanoma, there is interest in combining these strategies to take advantage of potential synergy. In order to study the ability of local radiation and anti-PD-1 immunotherapy to induce beneficial anti-tumor immune responses against distant, unirradiated tumors, we used two mouse models of metastatic melanoma in the brain, representing BRAF mutant and non-mutant tumors. Combination treatments produced a stronger systemic anti-tumor immune response than either treatment alone. This resulted in reduced tumor growth and larger numbers of activated, cytotoxic CD8
Identifiants
pubmed: 30546944
doi: 10.1080/2162402X.2018.1507669
pii: 1507669
pmc: PMC6287893
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e1507669Références
Nat Immunol. 2013 Mar;14(3):254-61
pubmed: 23291597
Cancer. 2011 Apr 15;117(8):1687-96
pubmed: 20960525
Sci Transl Med. 2016 Mar 2;8(328):328rv4
pubmed: 26936508
Br J Cancer. 2014 May 13;110(10):2560-8
pubmed: 24691423
Nat Rev Immunol. 2017 Mar;17(3):179-194
pubmed: 28138136
Nat Med. 2007 Sep;13(9):1050-9
pubmed: 17704786
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
N Engl J Med. 2012 Jun 28;366(26):2443-54
pubmed: 22658127
Brain. 2008 Mar;131(Pt 3):785-99
pubmed: 18156156
J Clin Oncol. 2005 Jun 20;23(18):4127-36
pubmed: 15961760
Acta Neuropathol Commun. 2014 Mar 07;2:27
pubmed: 24606807
Cancer Res. 2012 Aug 15;72(16):3967-76
pubmed: 22700877
Cancer Treat Rev. 2016 Apr;45:38-45
pubmed: 26975020
Int J Radiat Oncol Biol Phys. 2015 Jun 1;92(2):368-75
pubmed: 25754629
Cancer Immunol Res. 2013 Aug;1(2):92-8
pubmed: 24777500
J Biol Chem. 2015 Sep 4;290(36):21962-75
pubmed: 26205817
Expert Opin Biol Ther. 2017 Jun;17(6):765-780
pubmed: 28323504
J Pathol. 2014 Jan;232(2):199-209
pubmed: 24122236
J Neurosurg. 2011 Mar;114(3):769-79
pubmed: 20524829
Cell Rep. 2014 Dec 11;9(5):1812-1826
pubmed: 25464848
J Exp Med. 2011 Aug 1;208(8):1695-705
pubmed: 21788405
J Clin Oncol. 2013 Nov 20;31(33):4199-206
pubmed: 24127452
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
J Immunol. 2006 Dec 15;177(12):8448-55
pubmed: 17142742
N Engl J Med. 2012 Mar 8;366(10):925-31
pubmed: 22397654
Nat Genet. 2009 May;41(5):544-52
pubmed: 19282848
Cancer Treat Rev. 2015 Jun;41(6):503-10
pubmed: 25872878
N Engl J Med. 2015 Jan 22;372(4):311-9
pubmed: 25482239
J Neurooncol. 2003 Aug-Sep;64(1-2):55-61
pubmed: 12952286
Clin Immunol. 2009 Aug;132(2):153-65
pubmed: 19428306
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
J Clin Oncol. 2011 Apr 1;29(10):1239-46
pubmed: 21343559
Int J Mol Sci. 2014 Jan 10;15(1):927-43
pubmed: 24434638
Int J Radiat Biol. 2014 Mar;90(3):248-55
pubmed: 24350918
PLoS One. 2016 Jun 09;11(6):e0157164
pubmed: 27281029
Expert Rev Anticancer Ther. 2017 Jul;17(7):647-655
pubmed: 28604130
Ann Oncol. 2016 Mar;27(3):434-41
pubmed: 26712903
Melanoma Res. 2012 Jun;22(3):177-83
pubmed: 22495668
N Engl J Med. 2015 Jan 22;372(4):320-30
pubmed: 25399552
Cancer Immunol Res. 2015 Jun;3(6):610-9
pubmed: 25701325
Clin Cancer Res. 2011 Aug 15;17(16):5343-52
pubmed: 21737507
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
J Immunol. 2012 Dec 1;189(11):5147-54
pubmed: 23100512
Cancer Cell. 2013 Jul 8;24(1):120-9
pubmed: 23845444
J Transl Med. 2010 Jul 14;8:67
pubmed: 20630094
Br J Dermatol. 2011 Apr;164(4):776-84
pubmed: 21166657
Cancer Treat Rev. 2004 Oct;30(6):515-20
pubmed: 15325032
Cell. 2011 Jul 8;146(1):53-66
pubmed: 21729780
Oncologist. 2017 Aug;22(8):963-971
pubmed: 28476944
J Clin Oncol. 2014 Apr 1;32(10):1020-30
pubmed: 24590637
Eur J Cancer. 2017 Apr;75:169-178
pubmed: 28236768
Lancet Oncol. 2015 Apr;16(4):375-84
pubmed: 25795410
Eur J Cancer. 2017 Aug;81:116-129
pubmed: 28623775
Lancet Oncol. 2015 Aug;16(8):908-18
pubmed: 26115796
Clin Cancer Res. 2009 Sep 1;15(17):5379-88
pubmed: 19706802
Nature. 2014 Nov 27;515(7528):558-62
pubmed: 25428503
Oncoimmunology. 2015 Jun 9;5(1):e1057388
pubmed: 26942067
Am Soc Clin Oncol Educ Book. 2013;:399-403
pubmed: 23714560
Clin Cancer Res. 2014 May 15;20(10):2695-702
pubmed: 24647570
J Vis Exp. 2012 Sep 25;(67):null
pubmed: 23051742
Pigment Cell Melanoma Res. 2014 May;27(3):495-501
pubmed: 24460976
Front Oncol. 2016 Mar 09;6:49
pubmed: 27014624
Cancer Res. 2015 Apr 15;75(8):1760-9
pubmed: 25712125
Clin Cancer Res. 2008 Feb 15;14(4):1159-66
pubmed: 18281550
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
J Vis Exp. 2016 Jan 15;(107):e53287
pubmed: 26863490
N Engl J Med. 2015 Jun 25;372(26):2509-20
pubmed: 26028255
J Neurosurg. 2012 Aug;117(2):227-33
pubmed: 22702482
Int J Radiat Oncol Biol Phys. 2002 Apr 1;52(5):1277-87
pubmed: 11955740
Oncol Res Treat. 2016;39(6):326-34
pubmed: 27260656
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
J Immunother. 2016 Nov/Dec;39(9):367-372
pubmed: 27741091